Eupraxia Pharmaceuticals Inc Ordinary Shares EPRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $5.96
- Day Range
- $5.87–6.11
- 52-Week Range
- $3.85–9.32
- Bid/Ask
- $5.92 / $6.80
- Shares Outstanding
- 65.33M
- Market Cap
- $386.74M
- Volume/Avg
- 219,041 / 220,679
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 49
- Website
- https://www.eupraxiapharma.com
Valuation
|
Metric
|
EPRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.42 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EPRX
|
|---|---|
Quick Ratio | 18.95 |
Current Ratio | 19.30 |
Interest Coverage | — |
Quick Ratio
EPRX
Profitability
|
Metric
|
EPRX
|
|---|---|
Return on Assets (Normalized) | −48.70% |
Return on Equity (Normalized) | −88.86% |
Return on Invested Capital (Normalized) | −54.20% |
Return on Assets
EPRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Gtfxtjwgl | Scjnf | $111B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Cgdmzsy | Swwnph | $63B | |||
| argenx SE ADR
ARGX
| Tqkkmwzf | Qvkr | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ypvbtwyr | Bxtkvq | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Bfcsplvzjp | Wzfgsbc | $25B | |||
| BioNTech SE ADR
BNTX
| Wtfjkspv | Hlsmh | $22B | |||
| Incyte Corp
INCY
| Wrthztls | Rml | $21B | |||
| Moderna Inc
MRNA
| Jqwgtgvq | Nmgf | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Mhglsjcj | Ppfj | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Pqnxsrnxt | Kkv | $13B |
United States